AMRX FY 2020 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMRXAmneal Pharmaceuticals, Inc.

$4B

FY 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$2.0B+22.5% YoY

Gross Profit

$628M31.5% margin

Operating Income

$91M4.6% margin

Net Income

$91M4.6% margin

EPS (Diluted)

$0.61

Cash Flow

Operating Cash Flow

$379M

Free Cash Flow

$317M

Stock-Based Comp.

$21M

Balance Sheet

Total Assets

$4.0B

Total Liabilities

$3.6B

Stockholders' Equity

$303M

Cash & Equivalents

$341M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.0B	$1.6B	+22.5%
Gross Profit	$628M	$353M	+78.0%
Operating Income	$91M	-$249M	+136.7%
Net Income	$91M	-$362M	+125.2%